[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fl2D8cJlSP4wPwlTlg-ujX6Dl_9_9In0mFuRpMrFiUXM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":83,"rows":90},"Taiho Oncology, Inc.",[4],65,false,13,10,7960,25,1,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Advanced Solid Tumors",8,{"name":18,"count":19},"Acute Myeloid Leukemia",6,{"name":21,"count":22},"Myelodysplastic Syndromes",5,{"name":24,"count":25},"Gastric Cancer",3,{"name":27,"count":25},"Advanced Cholangiocarcinoma",{"name":29,"count":25},"Non-Small Cell Lung Cancer",{"name":31,"count":32},"Chronic Myelomonocytic Leukemia",2,{"name":34,"count":32},"Advanced Hepatocellular Carcinoma",[36,41,46,51,56,61,66,69,73,78],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02503423","Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","2022-10","ASTX660",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04657081","Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)","2024-09-30","Decitabine and Cedazuridine",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05403450","A Study of Tolinapant in Combination With Oral Decitabine\u002FCedazuridine and Oral Decitabine\u002FCedazuridine Alone in Participants With Relapsed\u002FRefractory Peripheral T-cell Lymphoma (R\u002FR PTCL)","2024-12-16","Tolinapant",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05945823","Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","2026-01-28","Futibatinib",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05973773","REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","2026-10-29","TAS6417",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04953910","Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment","2026-12","ASTX727",{"nctId":67,"briefTitle":68,"date":64,"intervention":65},"NCT04953897","Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment",{"nctId":70,"briefTitle":71,"date":64,"intervention":72},"NCT05727176","Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","TAS-120",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06506955","Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","2027-04","futibatinib",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04256317","A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","2027-11-01","Azacitidine",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,151,258,297,329,347,365,383,401,419,437,455,490,512,535,553,571,589,607,625,643,661,679,708,731,749,850,895,933,951,969,987,1005,1048,1070,1096,1121,1139,1164,1182,1200,1223,1257,1281,1306,1324,1350,1376,1394,1420,1438,1462,1480,1498,1525,1552,1576,1601,1627,1653,1678,1703,1726,1815],{"intervention":60,"totalTrials":25,"cells":92},{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":114,"PHASE4":147,"NA":149},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":12,"soonestReadout":105},[100],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT05967689","A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","RECRUITING",[86],"2028-08-31","2028-12-31","2023-07-31",220,[110],"Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations",[60,112,113],"CYP Cocktail","Transporter Cocktail",{"trials":115,"activeCount":32,"soonestReadout":59},[116,139],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":134},"NCT07128199","A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","ACTIVE_NOT_RECRUITING",[87],"2029-10-01","2032-10-01","2025-12-22",360,[126,127,128,129,130,131,132,133],"NSCLC, Stage IB-IIIA","Lung Cancer","Adjuvant","Post-surgical","EGFR","Exon 20","Early Stage Lung Cancer","Uncommon EGFR Mutations",[135,136,137,60,138],"Cisplatin","Carboplatin","Pemetrexed","Zipalertinib Matching-placebo",{"nctId":57,"briefTitle":58,"status":119,"phases":140,"primaryCompletion":59,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},[87],"2027-05-27","2023-12-18",285,[145],"Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation",[60],{"trials":148,"activeCount":95},[],{"trials":150,"activeCount":95},[],{"intervention":55,"totalTrials":152,"cells":153},7,{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":232,"PHASE4":254,"NA":256},{"trials":155,"activeCount":95},[],{"trials":157,"activeCount":95},[],{"trials":159,"activeCount":12,"soonestReadout":54},[160,176,194,209,220],{"nctId":161,"briefTitle":162,"status":163,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":175},"NCT02052778","A Study of TAS-120 in Patients With Advanced Solid Tumors","COMPLETED",[85,86],"2020-10-01","2024-10-22","2014-07-21",407,[170,171,172,173,174,24],"Cholangiocarcinoma","Urothelial Cancer","Advanced and Metastatic Cancer Patients With Tumors Harboring FGF\u002FFGFR Tumors","Primary CNS Tumors","Breast Cancer",[55],{"nctId":52,"briefTitle":53,"status":119,"phases":177,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":187},[86],"2027-01","2023-07-13",53,[182,183,184,185,186],"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer","Esophageal Adenocarcinoma","Esophageal Squamous Cell Cancer","Siewert Type 1 GEJ Cancer","Pancreatic Cancer",[55,188,135,189,190,191,192,193],"Pembrolizumab","5-FU","Oxaliplatin","Leucovorin","Levoleucovorin","Irinotecan",{"nctId":195,"briefTitle":196,"status":197,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":207},"NCT04024436","A Study of TAS-120 in Patients With Metastatic Breast Cancer","TERMINATED",[86],"2023-05-31","2023-09-06","2020-01-28",64,[204,205,206],"Metastatic Breast Cancer","FGFR 1 High Amplification","FGFR2 Amplification",[55,208],"Futibatinib plus Fulvestrant",{"nctId":210,"briefTitle":211,"status":197,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT04601857","Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma",[86],"2024-03-08","2025-09-16","2021-01-07",43,[218],"Advanced and Metastatic Urothelial Cancer",[55,188],{"nctId":221,"briefTitle":222,"status":197,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":231},"NCT04189445","Futibatinib in Patients With Specific FGFR Aberrations",[86],"2024-11-11","2020-08-05",115,[228,229,230],"Advanced or Metastatic Solid Tumor","Advanced or Metastatic Gastric or Gastroesophageal Cancer","Myeloid or Lymphoid Neoplasms (MLN)",[55],{"trials":233,"activeCount":12,"soonestReadout":76},[234,244],{"nctId":235,"briefTitle":236,"status":197,"phases":237,"primaryCompletion":238,"completion":238,"start":239,"enrollment":9,"conditions":240,"interventions":242},"NCT04093362","Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements",[87],"2024-04-22","2021-01-06",[27,241],"FGFR2 Gene Rearrangements",[55,135,243],"Gemcitabine",{"nctId":74,"briefTitle":75,"status":245,"phases":246,"primaryCompletion":76,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":252},"ENROLLING_BY_INVITATION",[86,87],"2027-04-30","2024-10-01",15,[251],"Advanced\u002FMetastatic Cancer",[77,253],"futibatinib, fulvestrant",{"trials":255,"activeCount":95},[],{"trials":257,"activeCount":95},[],{"intervention":135,"totalTrials":259,"cells":260},4,{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":283,"PHASE4":293,"NA":295},{"trials":262,"activeCount":95},[],{"trials":264,"activeCount":95},[],{"trials":266,"activeCount":12,"soonestReadout":54},[267,279],{"nctId":268,"briefTitle":269,"status":163,"phases":270,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":276},"NCT00072787","Phase 1\u002F2 Study of S-1 and Cisplatin in Advanced Gastric Cancer",[85,86],"2006-03","2006-05","2003-10",41,[24],[277,278],"S-1","cisplatin",{"nctId":52,"briefTitle":53,"status":119,"phases":280,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":281,"interventions":282},[86],[182,183,184,185,186],[55,188,135,189,190,191,192,193],{"trials":284,"activeCount":12,"soonestReadout":121},[285,289],{"nctId":117,"briefTitle":118,"status":119,"phases":286,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":287,"interventions":288},[87],[126,127,128,129,130,131,132,133],[135,136,137,60,138],{"nctId":235,"briefTitle":236,"status":197,"phases":290,"primaryCompletion":238,"completion":238,"start":239,"enrollment":9,"conditions":291,"interventions":292},[87],[27,241],[55,135,243],{"trials":294,"activeCount":95},[],{"trials":296,"activeCount":95},[],{"intervention":298,"totalTrials":32,"cells":299},"Venetoclax",{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":313,"PHASE4":325,"NA":327},{"trials":301,"activeCount":95},[],{"trials":303,"activeCount":95},[],{"trials":305,"activeCount":12,"soonestReadout":44},[306],{"nctId":42,"briefTitle":43,"status":119,"phases":307,"primaryCompletion":44,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":312},[85,86],"2026-12-31","2021-02-09",101,[18],[45,298],{"trials":314,"activeCount":12,"soonestReadout":81},[315],{"nctId":79,"briefTitle":80,"status":103,"phases":316,"primaryCompletion":81,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":322},[86,87],"2028-11-01","2020-05-21",316,[21,18,321,31],"Myelodysplastic Syndrome\u002FNeoplasm",[82,323,82,323,324,298],"ASTX030","Cedazuridine",{"trials":326,"activeCount":95},[],{"trials":328,"activeCount":95},[],{"intervention":136,"totalTrials":12,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":343,"NA":345},{"trials":332,"activeCount":95},[],{"trials":334,"activeCount":95},[],{"trials":336,"activeCount":95},[],{"trials":338,"activeCount":12,"soonestReadout":121},[339],{"nctId":117,"briefTitle":118,"status":119,"phases":340,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":341,"interventions":342},[87],[126,127,128,129,130,131,132,133],[135,136,137,60,138],{"trials":344,"activeCount":95},[],{"trials":346,"activeCount":95},[],{"intervention":137,"totalTrials":12,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":361,"NA":363},{"trials":350,"activeCount":95},[],{"trials":352,"activeCount":95},[],{"trials":354,"activeCount":95},[],{"trials":356,"activeCount":12,"soonestReadout":121},[357],{"nctId":117,"briefTitle":118,"status":119,"phases":358,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":359,"interventions":360},[87],[126,127,128,129,130,131,132,133],[135,136,137,60,138],{"trials":362,"activeCount":95},[],{"trials":364,"activeCount":95},[],{"intervention":138,"totalTrials":12,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":379,"NA":381},{"trials":368,"activeCount":95},[],{"trials":370,"activeCount":95},[],{"trials":372,"activeCount":95},[],{"trials":374,"activeCount":12,"soonestReadout":121},[375],{"nctId":117,"briefTitle":118,"status":119,"phases":376,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":377,"interventions":378},[87],[126,127,128,129,130,131,132,133],[135,136,137,60,138],{"trials":380,"activeCount":95},[],{"trials":382,"activeCount":95},[],{"intervention":82,"totalTrials":12,"cells":384},{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":397,"NA":399},{"trials":386,"activeCount":95},[],{"trials":388,"activeCount":95},[],{"trials":390,"activeCount":95},[],{"trials":392,"activeCount":12,"soonestReadout":81},[393],{"nctId":79,"briefTitle":80,"status":103,"phases":394,"primaryCompletion":81,"completion":317,"start":318,"enrollment":319,"conditions":395,"interventions":396},[86,87],[21,18,321,31],[82,323,82,323,324,298],{"trials":398,"activeCount":95},[],{"trials":400,"activeCount":95},[],{"intervention":323,"totalTrials":12,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":415,"NA":417},{"trials":404,"activeCount":95},[],{"trials":406,"activeCount":95},[],{"trials":408,"activeCount":95},[],{"trials":410,"activeCount":12,"soonestReadout":81},[411],{"nctId":79,"briefTitle":80,"status":103,"phases":412,"primaryCompletion":81,"completion":317,"start":318,"enrollment":319,"conditions":413,"interventions":414},[86,87],[21,18,321,31],[82,323,82,323,324,298],{"trials":416,"activeCount":95},[],{"trials":418,"activeCount":95},[],{"intervention":324,"totalTrials":12,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":433,"NA":435},{"trials":422,"activeCount":95},[],{"trials":424,"activeCount":95},[],{"trials":426,"activeCount":95},[],{"trials":428,"activeCount":12,"soonestReadout":81},[429],{"nctId":79,"briefTitle":80,"status":103,"phases":430,"primaryCompletion":81,"completion":317,"start":318,"enrollment":319,"conditions":431,"interventions":432},[86,87],[21,18,321,31],[82,323,82,323,324,298],{"trials":434,"activeCount":95},[],{"trials":436,"activeCount":95},[],{"intervention":253,"totalTrials":12,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":451,"NA":453},{"trials":440,"activeCount":95},[],{"trials":442,"activeCount":95},[],{"trials":444,"activeCount":95},[],{"trials":446,"activeCount":12,"soonestReadout":76},[447],{"nctId":74,"briefTitle":75,"status":245,"phases":448,"primaryCompletion":76,"completion":247,"start":248,"enrollment":249,"conditions":449,"interventions":450},[86,87],[251],[77,253],{"trials":452,"activeCount":95},[],{"trials":454,"activeCount":95},[],{"intervention":65,"totalTrials":25,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":473,"PHASE3":484,"PHASE4":486,"NA":488},{"trials":458,"activeCount":95},[],{"trials":460,"activeCount":32,"soonestReadout":64},[461,467],{"nctId":62,"briefTitle":63,"status":103,"phases":462,"primaryCompletion":64,"completion":64,"start":463,"enrollment":464,"conditions":465,"interventions":466},[85],"2022-12-23",27,[18,21],[65],{"nctId":67,"briefTitle":68,"status":103,"phases":468,"primaryCompletion":64,"completion":64,"start":469,"enrollment":470,"conditions":471,"interventions":472},[85],"2021-12-15",18,[18,21],[65],{"trials":474,"activeCount":12,"soonestReadout":479},[475],{"nctId":476,"briefTitle":477,"status":245,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT04093570","A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)",[86],"2027-12-31","2019-09-30",332,[18,31,21],[65],{"trials":485,"activeCount":95},[],{"trials":487,"activeCount":95},[],{"trials":489,"activeCount":95},[],{"intervention":188,"totalTrials":32,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":493,"activeCount":95},[],{"trials":495,"activeCount":95},[],{"trials":497,"activeCount":12,"soonestReadout":54},[498,502],{"nctId":52,"briefTitle":53,"status":119,"phases":499,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":500,"interventions":501},[86],[182,183,184,185,186],[55,188,135,189,190,191,192,193],{"nctId":210,"briefTitle":211,"status":197,"phases":503,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":504,"interventions":505},[86],[218],[55,188],{"trials":507,"activeCount":95},[],{"trials":509,"activeCount":95},[],{"trials":511,"activeCount":95},[],{"intervention":40,"totalTrials":12,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":515,"activeCount":95},[],{"trials":517,"activeCount":95},[],{"trials":519,"activeCount":12,"soonestReadout":39},[520],{"nctId":37,"briefTitle":38,"status":119,"phases":521,"primaryCompletion":39,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":528},[85,86],"2027-12","2015-07-14",253,[526,527],"Solid Tumors","Lymphoma",[40],{"trials":530,"activeCount":95},[],{"trials":532,"activeCount":95},[],{"trials":534,"activeCount":95},[],{"intervention":189,"totalTrials":12,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":538,"activeCount":95},[],{"trials":540,"activeCount":95},[],{"trials":542,"activeCount":12,"soonestReadout":54},[543],{"nctId":52,"briefTitle":53,"status":119,"phases":544,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":545,"interventions":546},[86],[182,183,184,185,186],[55,188,135,189,190,191,192,193],{"trials":548,"activeCount":95},[],{"trials":550,"activeCount":95},[],{"trials":552,"activeCount":95},[],{"intervention":190,"totalTrials":12,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":565,"PHASE4":567,"NA":569},{"trials":556,"activeCount":95},[],{"trials":558,"activeCount":95},[],{"trials":560,"activeCount":12,"soonestReadout":54},[561],{"nctId":52,"briefTitle":53,"status":119,"phases":562,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":563,"interventions":564},[86],[182,183,184,185,186],[55,188,135,189,190,191,192,193],{"trials":566,"activeCount":95},[],{"trials":568,"activeCount":95},[],{"trials":570,"activeCount":95},[],{"intervention":191,"totalTrials":12,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":574,"activeCount":95},[],{"trials":576,"activeCount":95},[],{"trials":578,"activeCount":12,"soonestReadout":54},[579],{"nctId":52,"briefTitle":53,"status":119,"phases":580,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":581,"interventions":582},[86],[182,183,184,185,186],[55,188,135,189,190,191,192,193],{"trials":584,"activeCount":95},[],{"trials":586,"activeCount":95},[],{"trials":588,"activeCount":95},[],{"intervention":192,"totalTrials":12,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":592,"activeCount":95},[],{"trials":594,"activeCount":95},[],{"trials":596,"activeCount":12,"soonestReadout":54},[597],{"nctId":52,"briefTitle":53,"status":119,"phases":598,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":599,"interventions":600},[86],[182,183,184,185,186],[55,188,135,189,190,191,192,193],{"trials":602,"activeCount":95},[],{"trials":604,"activeCount":95},[],{"trials":606,"activeCount":95},[],{"intervention":193,"totalTrials":12,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":610,"activeCount":95},[],{"trials":612,"activeCount":95},[],{"trials":614,"activeCount":12,"soonestReadout":54},[615],{"nctId":52,"briefTitle":53,"status":119,"phases":616,"primaryCompletion":54,"completion":178,"start":179,"enrollment":180,"conditions":617,"interventions":618},[86],[182,183,184,185,186],[55,188,135,189,190,191,192,193],{"trials":620,"activeCount":95},[],{"trials":622,"activeCount":95},[],{"trials":624,"activeCount":95},[],{"intervention":112,"totalTrials":12,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":637,"PHASE4":639,"NA":641},{"trials":628,"activeCount":95},[],{"trials":630,"activeCount":95},[],{"trials":632,"activeCount":12,"soonestReadout":105},[633],{"nctId":101,"briefTitle":102,"status":103,"phases":634,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":635,"interventions":636},[86],[110],[60,112,113],{"trials":638,"activeCount":95},[],{"trials":640,"activeCount":95},[],{"trials":642,"activeCount":95},[],{"intervention":113,"totalTrials":12,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":646,"activeCount":95},[],{"trials":648,"activeCount":95},[],{"trials":650,"activeCount":12,"soonestReadout":105},[651],{"nctId":101,"briefTitle":102,"status":103,"phases":652,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":653,"interventions":654},[86],[110],[60,112,113],{"trials":656,"activeCount":95},[],{"trials":658,"activeCount":95},[],{"trials":660,"activeCount":95},[],{"intervention":45,"totalTrials":12,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":673,"PHASE4":675,"NA":677},{"trials":664,"activeCount":95},[],{"trials":666,"activeCount":95},[],{"trials":668,"activeCount":12,"soonestReadout":44},[669],{"nctId":42,"briefTitle":43,"status":119,"phases":670,"primaryCompletion":44,"completion":308,"start":309,"enrollment":310,"conditions":671,"interventions":672},[85,86],[18],[45,298],{"trials":674,"activeCount":95},[],{"trials":676,"activeCount":95},[],{"trials":678,"activeCount":95},[],{"intervention":72,"totalTrials":32,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":682,"activeCount":95},[],{"trials":684,"activeCount":95},[],{"trials":686,"activeCount":12,"soonestReadout":64},[687],{"nctId":70,"briefTitle":71,"status":103,"phases":688,"primaryCompletion":64,"completion":64,"start":689,"enrollment":690,"conditions":691,"interventions":694},[86],"2023-07-05",120,[27,692,693],"FGFR2 Fusions","Gene Rearrangement",[72],{"trials":696,"activeCount":95},[],{"trials":698,"activeCount":95},[],{"trials":700,"activeCount":95},[701],{"nctId":702,"briefTitle":703,"status":704,"phases":705,"conditions":706,"interventions":707},"NCT04507503","Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements","APPROVED_FOR_MARKETING",[],[27],[72],{"intervention":50,"totalTrials":12,"cells":709},{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":711,"activeCount":95},[],{"trials":713,"activeCount":12,"soonestReadout":49},[714],{"nctId":47,"briefTitle":48,"status":119,"phases":715,"primaryCompletion":49,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},[85],"2026-03-31","2023-02-22",33,[720],"Relapsed\u002FRefractory Peripheral T-cell Lymphoma",[50,722],"Decitabine + Cedazuridine",{"trials":724,"activeCount":95},[],{"trials":726,"activeCount":95},[],{"trials":728,"activeCount":95},[],{"trials":730,"activeCount":95},[],{"intervention":722,"totalTrials":12,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":734,"activeCount":95},[],{"trials":736,"activeCount":12,"soonestReadout":49},[737],{"nctId":47,"briefTitle":48,"status":119,"phases":738,"primaryCompletion":49,"completion":716,"start":717,"enrollment":718,"conditions":739,"interventions":740},[85],[720],[50,722],{"trials":742,"activeCount":95},[],{"trials":744,"activeCount":95},[],{"trials":746,"activeCount":95},[],{"trials":748,"activeCount":95},[],{"intervention":277,"totalTrials":750,"cells":751},9,{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":777,"PHASE3":833,"PHASE4":846,"NA":848},{"trials":753,"activeCount":95},[],{"trials":755,"activeCount":95},[756,766],{"nctId":757,"briefTitle":758,"status":163,"phases":759,"primaryCompletion":760,"completion":761,"start":762,"enrollment":690,"conditions":763,"interventions":764},"NCT02454062","A Trial of TAS-114 in Combination With S-1",[85],"2016-12-27","2017-09-30","2013-03",[15],[765,277],"TAS-114",{"nctId":767,"briefTitle":768,"status":163,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT00400023","A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors",[85],"2007-05","2006-09",12,[774],"Tumors",[277,776],"FT",{"trials":778,"activeCount":95},[779,789,800,808,812,823],{"nctId":780,"briefTitle":781,"status":163,"phases":782,"primaryCompletion":761,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":788},"NCT02855125","A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1",[86],"2017-11-30","2016-08-29",128,[787],"Advanced or Metastatic Non-small Cell Lung Cancer",[765,277],{"nctId":790,"briefTitle":791,"status":163,"phases":792,"primaryCompletion":793,"completion":794,"start":795,"enrollment":796,"conditions":797,"interventions":799},"NCT00651833","Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer",[86],"2006-10","2007-07","2005-02",60,[798],"Advanced Non-Small Cell Lung Cancer",[277],{"nctId":801,"briefTitle":802,"status":163,"phases":803,"primaryCompletion":804,"completion":804,"start":795,"enrollment":805,"conditions":806,"interventions":807},"NCT00652561","Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer",[86],"2007-11",57,[798],[277],{"nctId":268,"briefTitle":269,"status":163,"phases":809,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":810,"interventions":811},[85,86],[24],[277,278],{"nctId":813,"briefTitle":814,"status":163,"phases":815,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},"NCT00652054","Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer",[86],"2007-06","2007-10","2005-06",39,[821],"Metastatic Pancreatic Cancer",[277],{"nctId":824,"briefTitle":825,"status":163,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":832},"NCT00651742","Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer",[86],"2008-07-08","2006-01-09",28,[831],"Locally Advanced or Metastatic Pancreatic Cancer",[277],{"trials":834,"activeCount":95},[835],{"nctId":836,"briefTitle":837,"status":197,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":844},"NCT01285557","Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial",[87],"2014-08-15","2011-04-14",361,[843],"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction",[277,845],"Fluorouracil\u002Fcisplatin",{"trials":847,"activeCount":95},[],{"trials":849,"activeCount":95},[],{"intervention":851,"totalTrials":25,"cells":852},"S-1\u002FCisplatin",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":876,"PHASE3":878,"PHASE4":891,"NA":893},{"trials":854,"activeCount":95},[],{"trials":856,"activeCount":95},[857,867],{"nctId":858,"briefTitle":859,"status":163,"phases":860,"primaryCompletion":861,"completion":861,"start":862,"enrollment":863,"conditions":864,"interventions":866},"NCT00398307","Evaluating Patients With Varying Degrees of Renal Function",[85],"2010-09","2006-02",24,[865],"Renal Impairment",[851],{"nctId":868,"briefTitle":869,"status":163,"phases":870,"primaryCompletion":871,"completion":872,"start":862,"enrollment":863,"conditions":873,"interventions":875},"NCT00398424","Evaluating Patients With Impaired Hepatic Function",[85],"2008-11","2009-03",[874],"Impaired Hepatic Function",[851],{"trials":877,"activeCount":95},[],{"trials":879,"activeCount":95},[880],{"nctId":881,"briefTitle":882,"status":163,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":889},"NCT00400179","A Safety and Efficacy Study in Patients With Gastric Cancer",[87],"2008-03","2008-04","2005-05",1053,[24],[851,890],"5-FU\u002Fcisplatin",{"trials":892,"activeCount":95},[],{"trials":894,"activeCount":95},[],{"intervention":896,"totalTrials":32,"cells":897},"Bevacizumab",{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":913,"PHASE3":915,"PHASE4":929,"NA":931},{"trials":899,"activeCount":95},[],{"trials":901,"activeCount":95},[902],{"nctId":903,"briefTitle":904,"status":163,"phases":905,"primaryCompletion":906,"completion":906,"start":907,"enrollment":6,"conditions":908,"interventions":910},"NCT01916447","A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.",[85],"2017-09","2013-09",[909],"Advanced Gastrointestinal Tumors",[911,912,896],"TAS-102","CPT-11",{"trials":914,"activeCount":95},[],{"trials":916,"activeCount":95},[917],{"nctId":918,"briefTitle":919,"status":163,"phases":920,"primaryCompletion":921,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT04737187","Phase III Study of Trifluridine\u002FTipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients",[87],"2022-07-19","2023-09-12","2020-11-25",492,[926],"Refractory Metastatic Colorectal Cancer",[928,896],"Trifluridine\u002FTipiracil",{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":95},[],{"intervention":890,"totalTrials":12,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":947,"NA":949},{"trials":936,"activeCount":95},[],{"trials":938,"activeCount":95},[],{"trials":940,"activeCount":95},[],{"trials":942,"activeCount":95},[943],{"nctId":881,"briefTitle":882,"status":163,"phases":944,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":945,"interventions":946},[87],[24],[851,890],{"trials":948,"activeCount":95},[],{"trials":950,"activeCount":95},[],{"intervention":928,"totalTrials":12,"cells":952},{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":965,"NA":967},{"trials":954,"activeCount":95},[],{"trials":956,"activeCount":95},[],{"trials":958,"activeCount":95},[],{"trials":960,"activeCount":95},[961],{"nctId":918,"briefTitle":919,"status":163,"phases":962,"primaryCompletion":921,"completion":922,"start":923,"enrollment":924,"conditions":963,"interventions":964},[87],[926],[928,896],{"trials":966,"activeCount":95},[],{"trials":968,"activeCount":95},[],{"intervention":243,"totalTrials":12,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":983,"NA":985},{"trials":972,"activeCount":95},[],{"trials":974,"activeCount":95},[],{"trials":976,"activeCount":95},[],{"trials":978,"activeCount":95},[979],{"nctId":235,"briefTitle":236,"status":197,"phases":980,"primaryCompletion":238,"completion":238,"start":239,"enrollment":9,"conditions":981,"interventions":982},[87],[27,241],[55,135,243],{"trials":984,"activeCount":95},[],{"trials":986,"activeCount":95},[],{"intervention":845,"totalTrials":12,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":95},[],{"trials":992,"activeCount":95},[],{"trials":994,"activeCount":95},[],{"trials":996,"activeCount":95},[997],{"nctId":836,"briefTitle":837,"status":197,"phases":998,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":999,"interventions":1000},[87],[843],[277,845],{"trials":1002,"activeCount":95},[],{"trials":1004,"activeCount":95},[],{"intervention":1006,"totalTrials":25,"cells":1007},"TAC-101",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1009,"activeCount":95},[],{"trials":1011,"activeCount":95},[],{"trials":1013,"activeCount":95},[1014,1023,1033],{"nctId":1015,"briefTitle":1016,"status":1017,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":95,"conditions":1021,"interventions":1022},"NCT00756782","A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma","WITHDRAWN",[86],"2008-12","2008-10",[34],[1006],{"nctId":1024,"briefTitle":1025,"status":197,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1032},"NCT00687596","Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy",[86],"2010-05-10","2008-08-01",52,[1031],"Hepatocellular Carcinoma",[1006],{"nctId":1034,"briefTitle":1035,"status":197,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1041},"NCT00667628","Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma",[86],"2009-12-22","2008-04-24",54,[34],[1006],{"trials":1043,"activeCount":95},[],{"trials":1045,"activeCount":95},[],{"trials":1047,"activeCount":95},[],{"intervention":765,"totalTrials":32,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1058,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1051,"activeCount":95},[],{"trials":1053,"activeCount":95},[1054],{"nctId":757,"briefTitle":758,"status":163,"phases":1055,"primaryCompletion":760,"completion":761,"start":762,"enrollment":690,"conditions":1056,"interventions":1057},[85],[15],[765,277],{"trials":1059,"activeCount":95},[1060],{"nctId":780,"briefTitle":781,"status":163,"phases":1061,"primaryCompletion":761,"completion":783,"start":784,"enrollment":785,"conditions":1062,"interventions":1063},[86],[787],[765,277],{"trials":1065,"activeCount":95},[],{"trials":1067,"activeCount":95},[],{"trials":1069,"activeCount":95},[],{"intervention":1071,"totalTrials":12,"cells":1072},"ASTX029",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1074,"activeCount":95},[],{"trials":1076,"activeCount":95},[],{"trials":1078,"activeCount":95},[1079],{"nctId":1080,"briefTitle":1081,"status":163,"phases":1082,"primaryCompletion":1083,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT03520075","Study of ASTX029 in Subjects With Advanced Solid Tumors",[85,86],"2024-08-01","2025-03-03","2018-05-07",192,[1088],"Solid Tumor, Adult",[1071,1071],{"trials":1091,"activeCount":95},[],{"trials":1093,"activeCount":95},[],{"trials":1095,"activeCount":95},[],{"intervention":1097,"totalTrials":12,"cells":1098},"Amrubicin",{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1100,"activeCount":95},[],{"trials":1102,"activeCount":95},[],{"trials":1104,"activeCount":95},[1105],{"nctId":1106,"briefTitle":1107,"status":197,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":470,"conditions":1111,"interventions":1113},"NCT01904253","A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy",[86],"2014-06","2013-07",[1112],"Small Cell Lung Cancer (SCLC)",[911,1097,1114],"Topotecan",{"trials":1116,"activeCount":95},[],{"trials":1118,"activeCount":95},[],{"trials":1120,"activeCount":95},[],{"intervention":1114,"totalTrials":12,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1124,"activeCount":95},[],{"trials":1126,"activeCount":95},[],{"trials":1128,"activeCount":95},[1129],{"nctId":1106,"briefTitle":1107,"status":197,"phases":1130,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":470,"conditions":1131,"interventions":1132},[86],[1112],[911,1097,1114],{"trials":1134,"activeCount":95},[],{"trials":1136,"activeCount":95},[],{"trials":1138,"activeCount":95},[],{"intervention":1140,"totalTrials":12,"cells":1141},"ASTX727 LD",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1158,"PHASE4":1160,"NA":1162},{"trials":1143,"activeCount":95},[],{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[1148],{"nctId":1149,"briefTitle":1150,"status":163,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1156},"NCT03502668","Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS",[85,86],"2026-01-13","2018-07-27",160,[21],[1140,1157],"ASTX727 SD",{"trials":1159,"activeCount":95},[],{"trials":1161,"activeCount":95},[],{"trials":1163,"activeCount":95},[],{"intervention":1157,"totalTrials":12,"cells":1165},{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1176,"PHASE4":1178,"NA":1180},{"trials":1167,"activeCount":95},[],{"trials":1169,"activeCount":95},[],{"trials":1171,"activeCount":95},[1172],{"nctId":1149,"briefTitle":1150,"status":163,"phases":1173,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":1174,"interventions":1175},[85,86],[21],[1140,1157],{"trials":1177,"activeCount":95},[],{"trials":1179,"activeCount":95},[],{"trials":1181,"activeCount":95},[],{"intervention":208,"totalTrials":12,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1194,"PHASE4":1196,"NA":1198},{"trials":1185,"activeCount":95},[],{"trials":1187,"activeCount":95},[],{"trials":1189,"activeCount":95},[1190],{"nctId":195,"briefTitle":196,"status":197,"phases":1191,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":1192,"interventions":1193},[86],[204,205,206],[55,208],{"trials":1195,"activeCount":95},[],{"trials":1197,"activeCount":95},[],{"trials":1199,"activeCount":95},[],{"intervention":1201,"totalTrials":12,"cells":1202},"nivolumab",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1204,"activeCount":95},[],{"trials":1206,"activeCount":95},[],{"trials":1208,"activeCount":95},[1209],{"nctId":1210,"briefTitle":1211,"status":163,"phases":1212,"primaryCompletion":1213,"completion":1214,"start":784,"enrollment":470,"conditions":1215,"interventions":1216},"NCT02860546","A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC",[86],"2017-08","2017-09-07",[926],[911,1201],{"trials":1218,"activeCount":95},[],{"trials":1220,"activeCount":95},[],{"trials":1222,"activeCount":95},[],{"intervention":1224,"totalTrials":32,"cells":1225},"TAS-119",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1249,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1227,"activeCount":95},[],{"trials":1229,"activeCount":95},[1230,1240],{"nctId":1231,"briefTitle":1232,"status":197,"phases":1233,"primaryCompletion":1234,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1238},"NCT02134067","Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",[85],"2018-07","2014-08",30,[15],[1224,1239],"Paclitaxel",{"nctId":1241,"briefTitle":1242,"status":197,"phases":1243,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":1246,"conditions":1247,"interventions":1248},"NCT02448589","An Investigation of TAS-119 Monotherapy",[85],"2019-08","2014-09",74,[15],[1224],{"trials":1250,"activeCount":95},[],{"trials":1252,"activeCount":95},[],{"trials":1254,"activeCount":95},[],{"trials":1256,"activeCount":95},[],{"intervention":1258,"totalTrials":12,"cells":1259},"TAS-116",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1273,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1261,"activeCount":95},[],{"trials":1263,"activeCount":95},[1264],{"nctId":1265,"briefTitle":1266,"status":163,"phases":1267,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1272},"NCT02965885","A Study of TAS-116 in Patients With Solid Tumors",[85],"2019-05-03","2017-07-10",31,[15],[1258],{"trials":1274,"activeCount":95},[],{"trials":1276,"activeCount":95},[],{"trials":1278,"activeCount":95},[],{"trials":1280,"activeCount":95},[],{"intervention":1282,"totalTrials":12,"cells":1283},"TAS-102 with a light tracer dose of [14C]FTD",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1304},{"trials":1285,"activeCount":95},[],{"trials":1287,"activeCount":95},[1288],{"nctId":1289,"briefTitle":1290,"status":163,"phases":1291,"primaryCompletion":1292,"completion":1293,"start":1294,"enrollment":16,"conditions":1295,"interventions":1296},"NCT02031055","Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors",[85],"2014-11","2015-06-17","2014-02",[15],[1282,1297,911],"TAS-102 with a light tracer dose of [14C] TPI",{"trials":1299,"activeCount":95},[],{"trials":1301,"activeCount":95},[],{"trials":1303,"activeCount":95},[],{"trials":1305,"activeCount":95},[],{"intervention":1297,"totalTrials":12,"cells":1307},{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1316,"PHASE3":1318,"PHASE4":1320,"NA":1322},{"trials":1309,"activeCount":95},[],{"trials":1311,"activeCount":95},[1312],{"nctId":1289,"briefTitle":1290,"status":163,"phases":1313,"primaryCompletion":1292,"completion":1293,"start":1294,"enrollment":16,"conditions":1314,"interventions":1315},[85],[15],[1282,1297,911],{"trials":1317,"activeCount":95},[],{"trials":1319,"activeCount":95},[],{"trials":1321,"activeCount":95},[],{"trials":1323,"activeCount":95},[],{"intervention":1325,"totalTrials":12,"cells":1326},"TAS0728",{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1328,"activeCount":95},[],{"trials":1330,"activeCount":95},[1331],{"nctId":1332,"briefTitle":1333,"status":197,"phases":1334,"primaryCompletion":1335,"completion":1335,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1341},"NCT03410927","A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities",[85],"2022-06-09","2018-04-06",19,[1339,1340],"Advanced Solid Tumors With HER2 Abnormalities","Advanced Solid Tumors With HER3 Abnormalities",[1325],{"trials":1343,"activeCount":95},[],{"trials":1345,"activeCount":95},[],{"trials":1347,"activeCount":95},[],{"trials":1349,"activeCount":95},[],{"intervention":1351,"totalTrials":12,"cells":1352},"TAS4464",{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1354,"activeCount":95},[],{"trials":1356,"activeCount":95},[1357],{"nctId":1358,"briefTitle":1359,"status":197,"phases":1360,"primaryCompletion":1361,"completion":1361,"start":1362,"enrollment":1363,"conditions":1364,"interventions":1367},"NCT02978235","A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma",[85],"2018-02-01","2017-03-01",11,[1365,1366],"Multiple Myeloma","NonHodgkin Lymphoma",[1351],{"trials":1369,"activeCount":95},[],{"trials":1371,"activeCount":95},[],{"trials":1373,"activeCount":95},[],{"trials":1375,"activeCount":95},[],{"intervention":1239,"totalTrials":12,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1379,"activeCount":95},[],{"trials":1381,"activeCount":95},[1382],{"nctId":1231,"briefTitle":1232,"status":197,"phases":1383,"primaryCompletion":1234,"completion":1234,"start":1235,"enrollment":1236,"conditions":1384,"interventions":1385},[85],[15],[1224,1239],{"trials":1387,"activeCount":95},[],{"trials":1389,"activeCount":95},[],{"trials":1391,"activeCount":95},[],{"trials":1393,"activeCount":95},[],{"intervention":1395,"totalTrials":12,"cells":1396},"ASTX295",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1412,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1398,"activeCount":95},[],{"trials":1400,"activeCount":95},[1401],{"nctId":1402,"briefTitle":1403,"status":197,"phases":1404,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1409,"interventions":1411},"NCT03975387","Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53",[85],"2023-09-11","2024-08-15","2019-07-11",106,[1410],"Solid Tumor",[1395],{"trials":1413,"activeCount":95},[],{"trials":1415,"activeCount":95},[],{"trials":1417,"activeCount":95},[],{"trials":1419,"activeCount":95},[],{"intervention":912,"totalTrials":12,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1423,"activeCount":95},[],{"trials":1425,"activeCount":95},[1426],{"nctId":903,"briefTitle":904,"status":163,"phases":1427,"primaryCompletion":906,"completion":906,"start":907,"enrollment":6,"conditions":1428,"interventions":1429},[85],[909],[911,912,896],{"trials":1431,"activeCount":95},[],{"trials":1433,"activeCount":95},[],{"trials":1435,"activeCount":95},[],{"trials":1437,"activeCount":95},[],{"intervention":1439,"totalTrials":12,"cells":1440},"TAS1440",{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1454,"PHASE3":1456,"PHASE4":1458,"NA":1460},{"trials":1442,"activeCount":95},[],{"trials":1444,"activeCount":95},[1445],{"nctId":1446,"briefTitle":1447,"status":197,"phases":1448,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1029,"conditions":1451,"interventions":1452},"NCT04282668","A Study of TAS1440 With ATRA in Subjects With r\u002Fr AML",[85],"2024-02-12","2020-03-15",[18],[1439,1453],"TAS1440 + ATRA",{"trials":1455,"activeCount":95},[],{"trials":1457,"activeCount":95},[],{"trials":1459,"activeCount":95},[],{"trials":1461,"activeCount":95},[],{"intervention":1453,"totalTrials":12,"cells":1463},{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1472,"PHASE3":1474,"PHASE4":1476,"NA":1478},{"trials":1465,"activeCount":95},[],{"trials":1467,"activeCount":95},[1468],{"nctId":1446,"briefTitle":1447,"status":197,"phases":1469,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1029,"conditions":1470,"interventions":1471},[85],[18],[1439,1453],{"trials":1473,"activeCount":95},[],{"trials":1475,"activeCount":95},[],{"trials":1477,"activeCount":95},[],{"trials":1479,"activeCount":95},[],{"intervention":776,"totalTrials":12,"cells":1481},{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1490,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1483,"activeCount":95},[],{"trials":1485,"activeCount":95},[1486],{"nctId":767,"briefTitle":768,"status":163,"phases":1487,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":1488,"interventions":1489},[85],[774],[277,776],{"trials":1491,"activeCount":95},[],{"trials":1493,"activeCount":95},[],{"trials":1495,"activeCount":95},[],{"trials":1497,"activeCount":95},[],{"intervention":1499,"totalTrials":12,"cells":1500},"TAS2940",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1502,"activeCount":95},[],{"trials":1504,"activeCount":95},[1505],{"nctId":1506,"briefTitle":1507,"status":197,"phases":1508,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1516},"NCT04982926","A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer",[85],"2025-02-26","2025-03-24","2021-09-16",29,[1410,1514,1515,174],"Glioblastoma","Non-small Cell Lung Cancer",[1499,1499],{"trials":1518,"activeCount":95},[],{"trials":1520,"activeCount":95},[],{"trials":1522,"activeCount":95},[],{"trials":1524,"activeCount":95},[],{"intervention":1526,"totalTrials":12,"cells":1527},"TAS-117",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1544,"PHASE3":1546,"PHASE4":1548,"NA":1550},{"trials":1529,"activeCount":95},[],{"trials":1531,"activeCount":95},[1532],{"nctId":1533,"briefTitle":1534,"status":197,"phases":1535,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":1539,"conditions":1540,"interventions":1543},"NCT04770246","TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations",[85],"2023-02-28","2023-03-06","2021-03-31",17,[1541,1542],"Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations","Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations",[1526,1526,1526,1526],{"trials":1545,"activeCount":95},[],{"trials":1547,"activeCount":95},[],{"trials":1549,"activeCount":95},[],{"trials":1551,"activeCount":95},[],{"intervention":1553,"totalTrials":12,"cells":1554},"TAS-114\u002Fcapecitabine",{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1568,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1556,"activeCount":95},[],{"trials":1558,"activeCount":95},[1559],{"nctId":1560,"briefTitle":1561,"status":163,"phases":1562,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":796,"conditions":1565,"interventions":1567},"NCT02025803","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",[85],"2017-07-07","2012-11",[1566],"Neoplasms",[1553],{"trials":1569,"activeCount":95},[],{"trials":1571,"activeCount":95},[],{"trials":1573,"activeCount":95},[],{"trials":1575,"activeCount":95},[],{"intervention":1577,"totalTrials":12,"cells":1578},"Trifluridine",{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1580,"activeCount":95},[],{"trials":1582,"activeCount":95},[1583],{"nctId":1584,"briefTitle":1585,"status":163,"phases":1586,"primaryCompletion":1587,"completion":1588,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1592},"NCT01867866","Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone",[85],"2013-10","2016-06","2013-05",44,[15],[911,1577],{"trials":1594,"activeCount":95},[],{"trials":1596,"activeCount":95},[],{"trials":1598,"activeCount":95},[],{"trials":1600,"activeCount":95},[],{"intervention":1602,"totalTrials":12,"cells":1603},"Futibatinib and Binimetinib",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1605,"activeCount":95},[],{"trials":1607,"activeCount":95},[1608],{"nctId":1609,"briefTitle":1610,"status":197,"phases":1611,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1618},"NCT04965818","Phase 1b\u002F2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer",[85],"2023-06-11","2023-09-21","2021-09-20",38,[1541,29,1617],"KRAS Gene Mutation",[1602],{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[],{"trials":1624,"activeCount":95},[],{"trials":1626,"activeCount":95},[],{"intervention":1628,"totalTrials":12,"cells":1629},"TAS3681",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1645,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1631,"activeCount":95},[],{"trials":1633,"activeCount":95},[1634],{"nctId":1635,"briefTitle":1636,"status":163,"phases":1637,"primaryCompletion":1638,"completion":1639,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1644},"NCT02566772","Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer",[85],"2022-08-09","2024-04-26","2016-03",130,[1643],"Metastatic Castration Resistant Prostate Cancer",[1628],{"trials":1646,"activeCount":95},[],{"trials":1648,"activeCount":95},[],{"trials":1650,"activeCount":95},[],{"trials":1652,"activeCount":95},[],{"intervention":1654,"totalTrials":12,"cells":1655},"TAS-102 oral solution",{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1670,"PHASE3":1672,"PHASE4":1674,"NA":1676},{"trials":1657,"activeCount":95},[],{"trials":1659,"activeCount":95},[1660],{"nctId":1661,"briefTitle":1662,"status":163,"phases":1663,"primaryCompletion":1664,"completion":1665,"start":1110,"enrollment":1666,"conditions":1667,"interventions":1669},"NCT01874522","Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI",[85],"2015-08","2015-11",46,[1668],"Advanced Solid Tumors (Excluding Breast Cancer)",[911,1654],{"trials":1671,"activeCount":95},[],{"trials":1673,"activeCount":95},[],{"trials":1675,"activeCount":95},[],{"trials":1677,"activeCount":95},[],{"intervention":1679,"totalTrials":12,"cells":1680},"TAS0612",{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1695,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1682,"activeCount":95},[],{"trials":1684,"activeCount":95},[1685],{"nctId":1686,"briefTitle":1687,"status":197,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":1691,"conditions":1692,"interventions":1694},"NCT04586270","A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer",[85],"2024-11-14","2020-10-15",47,[1693],"Advanced or Metastatic Solid Tumors",[1679],{"trials":1696,"activeCount":95},[],{"trials":1698,"activeCount":95},[],{"trials":1700,"activeCount":95},[],{"trials":1702,"activeCount":95},[],{"intervention":1704,"totalTrials":12,"cells":1705},"TAS3351",{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1718,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1707,"activeCount":95},[],{"trials":1709,"activeCount":95},[1710],{"nctId":1711,"briefTitle":1712,"status":197,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":470,"conditions":1716,"interventions":1717},"NCT05765734","A Study of TAS3351 in NSCLC Patients With EGFRmt",[85],"2025-03-14","2023-05-25",[29],[1704],{"trials":1719,"activeCount":95},[],{"trials":1721,"activeCount":95},[],{"trials":1723,"activeCount":95},[],{"trials":1725,"activeCount":95},[],{"intervention":911,"totalTrials":772,"cells":1727},{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1770,"PHASE3":1780,"PHASE4":1804,"NA":1806},{"trials":1729,"activeCount":95},[],{"trials":1731,"activeCount":95},[1732,1736,1743,1751,1755,1759,1763],{"nctId":1289,"briefTitle":1290,"status":163,"phases":1733,"primaryCompletion":1292,"completion":1293,"start":1294,"enrollment":16,"conditions":1734,"interventions":1735},[85],[15],[1282,1297,911],{"nctId":1737,"briefTitle":1738,"status":163,"phases":1739,"primaryCompletion":1588,"completion":1588,"start":1740,"enrollment":863,"conditions":1741,"interventions":1742},"NCT02301104","A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment",[85],"2015-01",[15],[911],{"nctId":1744,"briefTitle":1745,"status":163,"phases":1746,"primaryCompletion":1235,"completion":1747,"start":1748,"enrollment":1590,"conditions":1749,"interventions":1750},"NCT01867879","Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors",[85],"2015-04","2013-06",[1668],[911],{"nctId":903,"briefTitle":904,"status":163,"phases":1752,"primaryCompletion":906,"completion":906,"start":907,"enrollment":6,"conditions":1753,"interventions":1754},[85],[909],[911,912,896],{"nctId":1584,"briefTitle":1585,"status":163,"phases":1756,"primaryCompletion":1587,"completion":1588,"start":1589,"enrollment":1590,"conditions":1757,"interventions":1758},[85],[15],[911,1577],{"nctId":1661,"briefTitle":1662,"status":163,"phases":1760,"primaryCompletion":1664,"completion":1665,"start":1110,"enrollment":1666,"conditions":1761,"interventions":1762},[85],[1668],[911,1654],{"nctId":1764,"briefTitle":1765,"status":163,"phases":1766,"primaryCompletion":1767,"completion":1767,"start":1740,"enrollment":216,"conditions":1768,"interventions":1769},"NCT02301117","A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment",[85],"2019-06-19",[15],[911],{"trials":1771,"activeCount":95},[1772,1776],{"nctId":1106,"briefTitle":1107,"status":197,"phases":1773,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":470,"conditions":1774,"interventions":1775},[86],[1112],[911,1097,1114],{"nctId":1210,"briefTitle":1211,"status":163,"phases":1777,"primaryCompletion":1213,"completion":1214,"start":784,"enrollment":470,"conditions":1778,"interventions":1779},[86],[926],[911,1201],{"trials":1781,"activeCount":95},[1782,1793],{"nctId":1783,"briefTitle":1784,"status":163,"phases":1785,"primaryCompletion":1786,"completion":1787,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1792},"NCT01607957","Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies",[87],"2014-01-31","2016-05-23","2012-06-17",800,[1791],"Colorectal Cancer",[911],{"nctId":1794,"briefTitle":1795,"status":163,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1803},"NCT02500043","Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer",[87],"2018-04-30","2019-12-19","2016-02-24",507,[1802],"Refractory Metastatic Gastric Cancer",[911],{"trials":1805,"activeCount":95},[],{"trials":1807,"activeCount":95},[1808],{"nctId":1809,"briefTitle":1810,"status":704,"phases":1811,"conditions":1812,"interventions":1814},"NCT02286492","Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer",[],[1813],"Colorectal Cancer Metastatic",[911],{"intervention":1816,"totalTrials":12,"cells":1817},"Zipalertinib",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1819,"activeCount":95},[],{"trials":1821,"activeCount":95},[],{"trials":1823,"activeCount":95},[],{"trials":1825,"activeCount":95},[],{"trials":1827,"activeCount":95},[],{"trials":1829,"activeCount":95},[1830],{"nctId":1831,"briefTitle":1832,"status":1833,"phases":1834,"conditions":1835,"interventions":1836},"NCT07601399","An EAP Treatment Protocol of Zipalertinib","AVAILABLE",[],[29],[1816]]